Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

Journal of Clinical Oncology

Volumn 28, Issue 7, 2010, Pages 1168-1174

  Wick, Wolfgang ^a   Puduvalli, Vinay K ^a   Chamberlain, Marc C ^a   Van Den Bent, Martin J ^a   Carpentier, Antoine F ^a   Cher, Lawrence M ^a   Mason, Warren ^a   Weller, Michael ^a   Hong, Shengyan ^a   Musib, Luna ^a   Liepa, Astra M ^a   Thornton, Donald E ^a   Fine, Howard A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; ENZASTAURIN; ETOPOSIDE; INDOLE DERIVATIVE; IRINOTECAN; LOMUSTINE; LY 326020; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AORTA THROMBOSIS; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CONVULSION; CORTICOSTEROID THERAPY; COUGHING; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYSIPELAS; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HAZARD RATIO; HUMAN; INFECTION; LEUKOPENIA; LOADING DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; STOMATITIS; SYMPTOM; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR RECURRENCE; URINARY TRACT INFECTION; WELLBEING; WORLD HEALTH ORGANIZATION; AGED; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MORTALITY;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; INDOLES; LOMUSTINE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 77949891455     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.2595     Document Type: Article

References (45)

1. Behin A, Hoang-Xuan K, Carpentier AF, et al: Primary brain tumours in adults. Lancet 361:323-331, 2003 (Pubitemid 36126198)
2. DeAngelis LM: Chemotherapy for brain tumors: A new beginning. N Engl J Med 352:1036-1038, 2005
3. Grossman SA, Batara JF: Current management of glioblastoma multiforme. Semin Oncol 31: 635-644, 2004 (Pubitemid 39389014)
4. Shapiro WR, Green SB, Burger PC, et al: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71:1-9, 1989 (Pubitemid 19196544)
5. Fine HA, Dear KB, Loeffler JS, et al: Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597, 1993 (Pubitemid 23100496)
6. Stupp R, Mason WP, van den Bent MJ, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005
7. Levin VA, Wilson CB: Nitrosourea chemotherapy for primary malignant gliomas. Cancer Treat Rep 60:719-724, 1976
8. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
9. Chang SM, Theodosopoulos P, Lamborn K, et al: Temozolomide in the treatment of recurrent malignant glioma. Cancer 100:605-611, 2004 (Pubitemid 38124780)
10. Wick A, Felsberg J, Steinbach JP, et al: Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361, 2007 (Pubitemid 47325623)
11. Rosenthal MA, Ashley DL, Cher L: BCNU as second line therapy for recurrent high-grade glioma previously treated with temozolomide. J Clin Neurosci 11:374-375, 2004 (Pubitemid 38568473)
12. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520-529, 1994 (Pubitemid 24357278)
13. Berkman RA, Merrill MJ, Reinhold WC, et al: Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153-159, 1993 (Pubitemid 23037267)
14. Lamszus K, Ulbricht U, Matschke J, et al: Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399-1405, 2003 (Pubitemid 36418393)
15. Yoshiji H, Kuriyama S, Ways DK, et al: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59:4413-4418, 1999 (Pubitemid 29418762)
16. Livneh E, Fishman DD: Linking protein kinase C to cell-cycle control. Eur J Biochem 248:1-9, 1997 (Pubitemid 27356962)
17. Sano T, Lin H, Chen X, et al: Differential expression of MMAC/PTEN in glioblastoma multi-forme: Relationship to localization and prognosis. Cancer Res 59:1820-1824, 1999
18. Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39, 1998 (Pubitemid 28458022)
19. Koul D, Parthasarathy R, Shen R, et al: Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/ PTEN. Oncogene 20:6669-6678, 2001 (Pubitemid 33026073)
20. Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007 (Pubitemid 46424067)
21. Reardon D, Fink K, Mikkelsen T, et al: Randomized phase II study of cilengitide, an integrintargeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610-5617, 2008
22. Raizer JJ, Abrey LE, Wen P, et al: A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. J Clin Oncol 22:107s, 2004 (suppl; abstr 1502)
23. Graff JR, McNulty AM, Hanna KR, et al: The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-7469, 2005 (Pubitemid 41161281)
24. Keyes KA, Mann L, Sherman M, et al: LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53:133-140, 2004 (Pubitemid 38186992)
25. Teicher BA, Alvarez E, Menon K, et al: Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother Pharmacol 49: 69-77, 2002
26. Carducci MA, Musib L, Kies MS, et al: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24: 4092-4099, 2006 (Pubitemid 46622284)
27. Watkins V, Hong S, Lin B: Enzastaurin safety review: Data from phase I and phase II trials. J Clin Oncol 24:608s, 2006 (suppl; abstr 13077)
28. Fine HA, Kim L, Royce C, et al: Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 23:115s, 2005 (suppl; abstr 1504)
29. Levin VA, Crafts DC, Norman DM, et al: Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 47:329-335, 1977 (Pubitemid 8170121)
30. Weitzner MA, Meyers CA, Gelke CK, et al: The Functional Assessment of Cancer Therapy (FACT) scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151-1161, 1995
31. Beaumont JL, Victorson D, Peterman AH, et al: Validation of Functional Assessment of Cancer Therapy-Brain (FACT-Br) in patients with recurrent high-grade gliomas. Qual Life Res A-78, 2006 (abstr 1356)
32. van den Bent MJ, Wick W, Liepa AM, et al: Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme: Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU). J Clin Oncol 26:99s, 2008 (suppl; abstr 2040)
33. Oakes D: A concordance test for independence in the presence of censoring. Biometrics 38:451-455, 1982
34. Ballman KV, Buckner JC, Brown PD, et al: The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multi-forme. Neuro Oncol 9:29-38, 2007 (Pubitemid 46543486)
35. Rich JN, Reardon DA, Peery T, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142, 2004 (Pubitemid 41095125)
36. Raymond E, Brandes AA, Dittrich C, et al: Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26:4659-4665, 2008
37. Gerstner ER, Duda DG, di Tomaso E, et al: Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs 16:1895-1908, 2007
38. Cloughesy TF, Prados MD, Wen PY, et al: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:91s, 2008 (suppl, abstr 2010b)
39. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007 (Pubitemid 46075199)
40. Kreisl TN, Kotliarova S, Butman J, et al: A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-Oncology (in press)
41. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
42. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
43. Mischel PS, Cloughesy TF: Targeted molecular therapy of GBM. Brain Pathol 13:52-61, 2003 (Pubitemid 36133792)
44. Tabatabai G, Frank B, Wick A, et al: Synergistic anti-glioma activity of radiotherapy and enzastaurin. Ann Neurol 61:153-161, 2007 (Pubitemid 46363842)
45. Butowski NA, Lamborn K, Chang S, et al: Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS). J Clin Oncol 26:167s, 2008 (suppl; abstr 3559)